OFFICIAL PUBLICATION OF

by its subsidiary APPco

Price cut causes Invokana withdrawal

Megan Haggan 09/02/2015

Janssen-Cilag has removed INVOKANA (canagliflozin) from the PBS effective from 1 August 2015. The company was requested by the Department of Health, to either take a significant price reduction of close to 40% on Invokana, or face the medicine being removed from the PBS. A price cut of this magnitude would result in Invokana no

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Recent Comments
Popular Posts

‘Consumer confusion, pharmacist frustration’ if current system continues

The first and foremost role of "expanded scope" is the HMR and collaborative medication management. A clear no brainer which…

Big Pharma

‘I can feel the walls closing in on me as this snowballs’

I'm yet to encounter a corporate provider, Debbie, with the benefits you describe around quality improvement with the corporate business…

Kelly Abbott

‘I can feel the walls closing in on me as this snowballs’

I would argue quality varies in any profession. Most GPs will not refer to a provider where the quality is…

Big Pharma

Wesfarmers targets affordable healthcare

When healthcare is treated as a commodity and patients regarded as consumers, health outcomes are compromised and overall healthcare spending…

Edward Hatfield

Price cut causes Invokana withdrawal

Previous Rogue drug sellers or online pharmacies?

Next Interest rate cut good news for pharmacy

In the beginning

The signs of ageing

Hyperpigmentation

How to avoid dry skin

MENU

Previous Rogue drug sellers or online pharmacies?

Next Interest rate cut good news for pharmacy

Related Posts

MENU

Hi there! 👋 Looks like you’re not logged in.